Australia's most trusted
source of pharma news
Posted 12 May 2022 AM
Biologics are expected to account for more than half of all innovative drug sales by 2027 with three monoclonal antibodies leading the pack, says GlobalData.
According to the analytics company, biologics will surpass sales of innovative small molecules by a whooping US$120 billion in the next five years.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.